PCP
ADPT icon

Perbak Capital Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Perbak Capital Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,645
Closed -$176K – 10
2026
Q1 		$176K Buy
+12,645
New +$201K 0.04% 291

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Perbak Capital Partners's ADPT Position: Q2 2026 in Review

Perbak Capital Partners sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 12,645 shares — an estimated $176K sold.

Perbak Capital Partners first reported a position in ADPT in Q1 2026 and held it in 1 quarter. The position peaked at $176K in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Perbak Capital Partners reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 12,645 Adaptive Biotechnologies shares in Q2 2026, an estimated $176K.
  • Perbak Capital Partners first reported a position in Adaptive Biotechnologies in Q1 2026 and held it in 1 quarter.
  • Perbak Capital Partners's Adaptive Biotechnologies position peaked at $176K in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.